{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:11:04Z","timestamp":1788970264426,"version":"build-2803163510"},"reference-count":66,"publisher":"American Chemical Society (ACS)","issue":"8","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004702","name":"Universit? degli Studi di Genova","doi-asserted-by":"publisher","award":["100008-2022-KC-FRA_ANATOMIA"],"award-info":[{"award-number":["100008-2022-KC-FRA_ANATOMIA"]}],"id":[{"id":"10.13039\/501100004702","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell?Istruzione, dell?Universit? e della Ricerca","doi-asserted-by":"publisher","award":["M4C2-I1.3 - PE_00000019"],"award-info":[{"award-number":["M4C2-I1.3 - PE_00000019"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell?Istruzione, dell?Universit? e della Ricerca","doi-asserted-by":"publisher","award":["PRIN2020PBS5MJ"],"award-info":[{"award-number":["PRIN2020PBS5MJ"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Trastuzumab-deruxtecan (T-DXd) is a clinically effective antibody\u2013drug conjugate (ADC) with activity across HER2-amplified, HER2-low, and ultralow breast cancers. Despite its clinical success, how its nanoscale intracellular trafficking and processing shape therapeutic outcomes remains incompletely defined. Given the central role of HER2 internalization and lysosomal processing in ADC pharmacology, we investigated the spatiotemporal intracellular response to T-DXd in human HER2-positive breast cancer cell models. By integrating biochemical analyses with light and electron microscopy-based nanoscale imaging, and employing orthogonal nanoscale probes, including BSA\u2013gold nanoparticles and nanogold-based labeling, together with proteomic profiling, we reconstructed the temporal sequence of T-DXd action over 72 h. An early phase (2\u201324 h) was characterized by rapid HER2 phosphorylation, sustained ERK signaling, metabolic activation, and TFEB-driven lysosomal engagement, consistent with active drug processing. Nanoscale probing of the endocytic pathway using BSA\u2013gold nanoparticles demonstrated a marked expansion of the lysosomal compartment, with increased lysosome number and size, supporting the concept that T-DXd actively remodels lysosomal architecture rather then passively exploiting it as a delivery site. A transitional phase at 48 h revealed pronounced lysosomal accumulation of T-DXd and extensive organelle remodeling. By 72 h, cells entered a late phase marked by mitochondrial dysfunction, nuclear envelope stress, and DNA damage, accompanied by the emergence of nanoscale contacts among lysosomes, mitochondria, and the nucleus, suggestive of coordinated organelle failure. Proteomic analysis indicated activation of inflammatory and stress-associated pathways, including TNF\u03b1\/NF-\u03baB signaling, supported by increased release of IL-6, IL-8, and TNF-\u03b1. Collectively, this spatiotemporal framework identifies compartment-specific nanoscale vulnerabilities engaged by T-DXd and highlights ERK-dependent signaling and lysosomal function as potential targets for rational combination strategies in HER2-positive breast cancer.<\/jats:p>","DOI":"10.1021\/acsnanomed.6c00097","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T17:19:53Z","timestamp":1783012793000},"page":"2071-2090","source":"Crossref","is-referenced-by-count":0,"title":["Intracellular\nNanopharmacology of Trastuzumab Deruxtecan\nReveals Lysosome-Centered Organelle Vulnerabilities in HER2-Positive\nBreast Cancer Cells"],"prefix":"10.1021","volume":"1","author":[{"given":"Erica","family":"Tagliatti","sequence":"first","affiliation":[{"name":"IRCCS Humanitas Research Hospital , , Via Alessandro Manzoni 56 , ,","place":["Rozzano, Milan, Italy, 20089"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Gagliani","sequence":"additional","affiliation":[{"name":"University of Genoa , , Via Antonio De Toni 14 , ,","place":["Genoa, Italy, 16132"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Bellese","sequence":"additional","affiliation":[{"name":"University of Genoa , , Via Antonio De Toni 14 , ,","place":["Genoa, Italy, 16132"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahnaz","family":"Salamat","sequence":"additional","affiliation":[{"name":"University of Genoa , , Via Antonio De Toni 14 , ,","place":["Genoa, Italy, 16132"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Crippa","sequence":"additional","affiliation":[{"name":"IRCCS Ospedale San Raffaele , , Via Olgettina 60 , ,","place":["Milan, Italy, 20132"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Sollazzo","sequence":"additional","affiliation":[{"name":"University of Bologna , , Via Zamboni, 33 , ,","place":["Bologna, Italy, 40126"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9986-1358","authenticated-orcid":true,"given":"Andrea","family":"Abbona","sequence":"additional","affiliation":[{"name":"Fondazione Arco , Via Antonio Carle, 25 , ,","place":["Cuneo, Italy, 12100"]},{"name":"Azienda Ospedaliera Santa Croce e Carle , Via Michele Coppino 26 , ,","place":["Cuneo, Italy, 12100"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Paccagnella","sequence":"additional","affiliation":[{"name":"Fondazione Arco , Via Antonio Carle, 25 , ,","place":["Cuneo, Italy, 12100"]},{"name":"Azienda Ospedaliera Santa Croce e Carle , Via Michele Coppino 26 , ,","place":["Cuneo, Italy, 12100"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Arnaldi","sequence":"additional","affiliation":[{"name":"University of Genoa , , Via Antonio De Toni 14 , ,","place":["Genoa, Italy, 16132"]},{"name":"CNR Institute of Neuroscience , Via Raoul Follereau 3 , ,","place":["Milano, Italy, 20854"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucilla","family":"Rossi","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Giannina Gaslini , , Via Gerolamo Gaslini 5 , ,","place":["Genoa, Italy, 16147"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Petretto","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Giannina Gaslini , , Via Gerolamo Gaslini 5 , ,","place":["Genoa, Italy, 16147"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Rusmini","sequence":"additional","affiliation":[{"name":"Universita\u0300 degli Studi di Milano , , Via Giuseppe Balzaretti 9 , ,","place":["Milan, Italy, 20133"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Crippa","sequence":"additional","affiliation":[{"name":"Universita\u0300 degli Studi di Milano , , Via Giuseppe Balzaretti 9 , ,","place":["Milan, Italy, 20133"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Carlo","family":"Merlano","sequence":"additional","affiliation":[{"name":"FPO-IRCCS , , Viale della Ricerca 7 , ,","place":["Candiolo, Italy, 10060"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ornella","family":"Garrone","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , , Via Francesco Sforza 28 , ,","place":["Milano, Italy, 20122"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Porcelli","sequence":"additional","affiliation":[{"name":"University of Bologna , , Via Zamboni 33 , ,","place":["Bologna, Italy, 40126"]},{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna , Via Giuseppe Massarenti 9 , ,","place":["Bologna, Italy, 40138"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Matteoli","sequence":"additional","affiliation":[{"name":"IRCCS Humanitas Research Hospital , , Via Alessandro Manzoni 56 , ,","place":["Rozzano, Milan, Italy, 20089"]},{"name":"CNR Institute of Neuroscience , Via Raoul Follereau 3 , ,","place":["Milano, Italy, 20854"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Falletta","sequence":"additional","affiliation":[{"name":"IRCCS Ospedale San Raffaele , , Via Olgettina 60 , ,","place":["Milan, Italy, 20132"]},{"name":"Vita-Salute San Raffaele University , Via Olgettina 60 , ,","place":["Milan, Italy, 20132"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizio","family":"Castagnola","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliera Metropolitana , Largo Rosanna Benzi 10 , ,","place":["Genova, Italy, 16132"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9218-8933","authenticated-orcid":true,"given":"Katia","family":"Cortese","sequence":"additional","affiliation":[{"name":"University of Genoa , , Via Antonio De Toni 14 , ,","place":["Genoa, Italy, 16132"]},{"name":"IRCCS Azienda Ospedaliera Metropolitana , Largo Rosanna Benzi 10 , ,","place":["Genova, Italy, 16132"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"issue":"1","key":"2026090910072822400_cit1","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1186\/s12889-025-24036-w","article-title":"Global Determinants of Breast Cancer Mortality: A Comprehensive\nMeta-Analysis of Clinical, Demographic, and Lifestyle Risk Factors","volume":"25","author":"Dessie","year":"2025","journal-title":"BMC Public Health"},{"issue":"9","key":"2026090910072822400_cit2","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.62347\/FOWU3488","article-title":"Therapeutic Challenges\nin HER2-Targeted Antibody Therapies: Trastuzumab and Its ADC Derivatives\nin Breast Cancer","volume":"15","author":"Lin","year":"2025","journal-title":"Am. J. Cancer Res."},{"issue":"6","key":"2026090910072822400_cit3","doi-asserted-by":"publisher","first-page":"737","DOI":"10.3390\/cancers11060737","article-title":"Preclinical Characteristics of the\nIrreversible Pan- Her Kinase Inhibitor Neratinib Compared with Lapatinib:\nImplications for the Treatment of HER2- Positive and HER2-Mutated\nBreast Cancer","volume":"11","author":"Collins","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"12","key":"2026090910072822400_cit4","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1002\/ijc.32408","article-title":"Fam-] Trastuzumab Deruxtecan, Antitumor\nActivity Is Dependent on HER2 Expression Level Rather than on HER2\nAmplification","volume":"145","author":"Takegawa","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"1","key":"2026090910072822400_cit5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41698-025-00801-3","article-title":"Real Life Outcome Analysis of Breast\nCancer Brain Metastases Treated with Trastuzumab Deruxtecan","volume":"9","author":"Fabi","year":"2025","journal-title":"NPJ. Precis. Oncol."},{"issue":"20","key":"2026090910072822400_cit6","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a,\na Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor,\nDemonstrates a Promising Antitumor Efficacy with Differentiation from\nT-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"2026090910072822400_cit7","doi-asserted-by":"publisher","first-page":"e0222280","DOI":"10.1371\/journal.pone.0222280","article-title":"Fam-] Trastuzumab Deruxtecan\n(DS-8201a)Induced Antitumor Immunity Is Facilitated by the Anti\u2013CTLA-4\nAntibody in a Mouse Model","volume":"14","author":"Iwata","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"2026090910072822400_cit8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1248\/cpb.c18-00744","article-title":"The Latest\nResearch and Development into the Antibody\u2013Drug Conjugate,\n[Fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy","volume":"67","author":"Nakada","year":"2019","journal-title":"Chem. Pharm. Bull. (Tokyo)."},{"issue":"1","key":"2026090910072822400_cit9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan\nin Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"2026090910072822400_cit10","doi-asserted-by":"publisher","first-page":"7496","DOI":"10.1038\/s41467-023-43324-w","article-title":"Comprehensive\nGenomic\nCharacterization of HER2-Low and HER2\u20130 Breast Cancer","volume":"14","author":"Tarantino","year":"2023","journal-title":"Nat. Commun."},{"key":"2026090910072822400_cit11","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1158\/2159-8290.CD-25-0647","article-title":"Trastuzumab Deruxtecan (T-DXd) Resistance via Loss\nof HER2 Expression and Binding","volume":"16","author":"Chen","year":"2026","journal-title":"Cancer Discov"},{"key":"2026090910072822400_cit12","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.3390\/ijms22094774","article-title":"Trastuzumab\nDeruxtecan: Changing\nthe Destiny of Her2 Expressing Solid Tumors","volume":"22","author":"Indini","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"issue":"10371","key":"2026090910072822400_cit13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine\nin Patients with HER2-Positive Metastatic Breast Cancer: Updated Results\nfrom DESTINY-Breast03, a Randomised, Open-Label, Phase 3 Trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"2026090910072822400_cit14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab\nDeruxtecan in Patients With HER2-Expressing Solid Tumors: Primary\nResults From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"2026090910072822400_cit15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40364-024-00715-5","article-title":"Histamine N-Methyltransferase\n(HNMT) as a Potential Auxiliary Biomarker for Predicting Adaptability\nto Anti-HER2 Drug Treatment in Breast Cancer Patients","volume":"13","author":"Cheng","year":"2025","journal-title":"Biomark. Res."},{"issue":"9","key":"2026090910072822400_cit16","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00546","article-title":"Multiplex Spatial\nProteomic Analysis of HER2-Positive Breast Tumors Reveals Unique Molecular\nand Immunologic Features Associated With Treatment Response","author":"Hennessy","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"2026090910072822400_cit17","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective\nExtracellular Payload Release and Immunomodulatory Interactions Govern\nthe Therapeutic Effect of Trastuzumab Deruxtecan (T-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat. Commun."},{"issue":"7","key":"2026090910072822400_cit18","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1158\/1535-7163.MCT-17-0019","article-title":"Tumor-Associated\nMacrophages Can Contribute to Antitumor Activity through Fc\u03b3R-Mediated\nProcessing of Antibody-Drug Conjugates","volume":"16","author":"Li","year":"2017","journal-title":"Mol.\nCancer Ther."},{"key":"2026090910072822400_cit19","doi-asserted-by":"publisher","first-page":"103404","DOI":"10.1016\/j.eclinm.2025.103404","article-title":"Trastuzumab Deruxtecan\nin Patients from China with\nPreviously Treated Human Epidermal Growth Factor Receptor 2\u2013Positive\nLocally Advanced\/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma\n(DESTINY-Gastric06): Results from a Single-Arm","volume":"87","author":"Peng","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"1","key":"2026090910072822400_cit20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab\nDeruxtecan in Patients With HER2-Expressing Solid Tumors: Primary\nResults From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"2026090910072822400_cit21","doi-asserted-by":"publisher","first-page":"e15012","DOI":"10.1200\/JCO.2025.43.16_suppl.e15012","article-title":"Pan-Tumor Application\nof Trastuzumab Deruxtecan (T-DXd) Monotherapy in HER2 3+ Advanced\nSolid Tumors: A Pilot Study Challenging Existing Treatment Restrictions","volume":"43","author":"Rong","year":"2025","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"2026090910072822400_cit22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-024-01899-w","article-title":"Therapeutic Advances\nof Targeting Receptor Tyrosine\nKinases in Cancer","volume":"9","author":"Tomuleasa","year":"2024","journal-title":"Signal Transduct. Target.\nTher."},{"issue":"9","key":"2026090910072822400_cit23","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104436","article-title":"ErbB\/HER Family\nin Cancer Immunology: Therapeutic Advances and Mechanisms","volume":"30","author":"Yin","year":"2025","journal-title":"Drug Discovery Today"},{"issue":"24","key":"2026090910072822400_cit24","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000038508","article-title":"HER2\/PI3K\/AKT Pathway\nin HER2-Positive Breast Cancer: A Review","volume":"103","author":"Pan","year":"2024","journal-title":"Medicine"},{"key":"2026090910072822400_cit25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB Signalling Network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2026090910072822400_cit26","doi-asserted-by":"publisher","first-page":"6102","DOI":"10.1038\/sj.onc.1203973","article-title":"Molecular Mechanisms Underlying ErbB2\/HER2 Action in\nBreast Cancer","volume":"19","author":"Harari","year":"2000","journal-title":"Oncogene"},{"key":"2026090910072822400_cit27","doi-asserted-by":"publisher","first-page":"5268","DOI":"10.1091\/mbc.e04-07-0591","article-title":"Endocytosis and\nSorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab\nand Geldanamycin","volume":"15","author":"Austin","year":"2004","journal-title":"Mol. Biol. Cell"},{"key":"2026090910072822400_cit28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1091\/mbc.e12-04-0282","article-title":"The HSP90\nInhibitor Geldanamycin\nPerturbs Endosomal Structure and Drives Recycling ErbB2 and Transferrin\nto Modified MVBs\/Lysosomal Compartments","volume":"24","author":"Cortese","year":"2013","journal-title":"Mol.\nBiol. Cell"},{"key":"2026090910072822400_cit29","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.canlet.2016.08.026","article-title":"Neratinib\nInduces ErbB2 Ubiquitylation and Endocytic Degradation via HSP90 Dissociation\nin Breast Cancer Cells","volume":"382","author":"Zhang","year":"2016","journal-title":"Cancer Lett."},{"issue":"7","key":"2026090910072822400_cit30","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1369\/00221554211026297","article-title":"Imaging of Endocytic\nTrafficking\nand Extracellular Vesicles Released Under Neratinib Treatment in ERBB2+\nBreast Cancer Cells","volume":"69","author":"Santamaria","year":"2021","journal-title":"Journal of Histochemistry\nand Cytochemistry"},{"key":"2026090910072822400_cit31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115633","article-title":"Neratinib Is a TFEB and TFE3 Activator\nThat Potentiates Autophagy and Unbalances Energy Metabolism in ERBB2+\nBreast Cancer Cells","volume":"213","author":"Bellese","year":"2023","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"2026090910072822400_cit32","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3390\/membranes11030199","article-title":"Trastuzumab\nModulates the Protein\nCargo of Extracellular Vesicles Released by Erbb2+ Breast Cancer Cells","volume":"11","author":"Marconi","year":"2021","journal-title":"Membranes (Basel)"},{"issue":"36","key":"2026090910072822400_cit33","doi-asserted-by":"publisher","first-page":"60109","DOI":"10.18632\/oncotarget.17686","article-title":"Cooperative\nbut Distinct Early Co-Signaling\nEvents Originate from ERBB2 and ERBB1 Receptors upon Trastuzumab Treatment\nin Breast Cancer Cells","volume":"8","author":"Bagnato","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"2026090910072822400_cit34","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1080\/15548627.2021.1907168","article-title":"Autophagy Inhibition Perturbs ERBB2\nTrafficking and Abolishes Tumorigenesis in ERBB2-Driven Breast Cancer","volume":"17","author":"Hao","year":"2021","journal-title":"Autophagy"},{"issue":"12","key":"2026090910072822400_cit35","doi-asserted-by":"publisher","first-page":"4269","DOI":"10.1158\/0008-5472.CAN-10-3504","article-title":"Nuclear\nErbB2 Enhances Translation\nand Cell Growth by Activating Transcription of Ribosomal RNA Genes","volume":"71","author":"Li","year":"2011","journal-title":"Cancer Res."},{"key":"2026090910072822400_cit36","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251332473","article-title":"The Mechanisms\nof HER2 Targeted ADCs\nAre Dependent on Rab GTPases","volume":"17","author":"Medhus","year":"2025","journal-title":"Ther. Adv. Med.\nOncol."},{"key":"2026090910072822400_cit37","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1002\/ijc.70235","article-title":"99m)Tc-HP-Ark2\nSPECT\/CT Imaging Reveals\nDynamic HER2 Regulation in Trastuzumab Resistance and Its Reversal\nby PI3K Inhibition","volume":"158","author":"Lin","year":"2026","journal-title":"Int. J. Cancer"},{"issue":"4","key":"2026090910072822400_cit38","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A Functional Genetic\nApproach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab\nResistance in Breast Cancer","volume":"12","author":"Berns","year":"2007","journal-title":"Cancer Cell"},{"key":"2026090910072822400_cit39","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.3390\/biology14121654","article-title":"3D Breast Cancer Spheroids Reveal\nArchitecture-Dependent HER2 Expression and Signaling","volume":"14","author":"Arnaldi","year":"2025","journal-title":"Biology."},{"key":"2026090910072822400_cit40","doi-asserted-by":"publisher","DOI":"10.1021\/acsnanomed.6c00020","article-title":"Theranostic Frontiers in HER2-Positive\nBreast Cancer:\nNanomedicine Meets Morphology","author":"Banerjee","year":"2026","journal-title":"ACS Nano Medicine"},{"issue":"12","key":"2026090910072822400_cit41","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/s41573-019-0036-1","article-title":"Lysosomes\nas a Therapeutic Target","volume":"18","author":"Bonam","year":"2019","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"6767","key":"2026090910072822400_cit42","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1126\/science.adn8754","article-title":"Lysosomes Signal through the Epigenome\nto Regulate Longevity across Generations","volume":"389","author":"Zhang","year":"2025","journal-title":"Science"},{"issue":"2","key":"2026090910072822400_cit43","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41580-019-0185-4","article-title":"Lysosomes as Dynamic Regulators of Cell and Organismal\nHomeostasis","volume":"21","author":"Ballabio","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"2026090910072822400_cit44","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13046-017-0615-0","article-title":"Cooperative Antitumor Activities\nof Carnosic Acid and Trastuzumab in ERBB2+ Breast Cancer Cells","volume":"36","author":"D\u2019Alesio","year":"2017","journal-title":"Journal of Experimental and Clinical Cancer Research"},{"issue":"5","key":"2026090910072822400_cit45","doi-asserted-by":"publisher","first-page":"1027a","DOI":"10.1074\/mcp.TIR118.001270","article-title":"Protein Aggregation\nCapture on Microparticles Enables Multipurpose\nProteomics Sample Preparation","volume":"18","author":"Batth","year":"2019","journal-title":"Molecular Cellular\nProteomics"},{"issue":"1","key":"2026090910072822400_cit46","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate:\nA Practical and\nPowerful Approach to Multiple Testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"Journal\nof the Royal Statistical Society, Methodology"},{"issue":"1","key":"2026090910072822400_cit47","doi-asserted-by":"publisher","first-page":"16906","DOI":"10.1038\/s41598-020-73835-1","article-title":"Direct Stimulation\nof ERBB2 Highlights a Novel Cytostatic Signaling Pathway Driven by\nthe Receptor Thr701 Phosphorylation","volume":"10","author":"Gaviraghi","year":"2020","journal-title":"Sci. Rep."},{"issue":"6","key":"2026090910072822400_cit48","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41580-018-0003-4","article-title":"Mechanism and Medical\nImplications of Mammalian Autophagy","volume":"19","author":"Dikic","year":"2018","journal-title":"Nat. Rev.\nMol. Cell Biol."},{"issue":"May","key":"2026090910072822400_cit49","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2020.101510","article-title":"Integrated Molecular\nSignaling Involving Mitochondrial Dysfunction and Alteration of Cell\nMetabolism Induced by Tyrosine Kinase Inhibitors in Cancer","volume":"36","author":"Rodriguez-Hernandez","year":"2020","journal-title":"Redox Biol."},{"issue":"1","key":"2026090910072822400_cit50","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s11658-026-00889-w","article-title":"Persistent PI3K\u2013AKT Signaling\nFortifies Cellular Defense against Oxidative Stress and Ferroptosis\nthrough Augmented Mitochondrial Fitness","volume":"31","author":"Xie","year":"2026","journal-title":"Cell.\nMol. Biol. Lett."},{"issue":"1","key":"2026090910072822400_cit51","doi-asserted-by":"publisher","first-page":"5119","DOI":"10.1038\/s41467-024-49543-z","article-title":"A Tripartite Organelle Platform Links\nGrowth Factor Receptor Signaling to Mitochondrial Metabolism","volume":"15","author":"Mesa","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"2026090910072822400_cit52","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/s41467-019-09253-3","article-title":"Coming Together\nto Define Membrane\nContact Sites","volume":"10","author":"Scorrano","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"2026090910072822400_cit53","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation\nand Tumor Progression: Signaling Pathways and Targeted\nIntervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"2026090910072822400_cit54","doi-asserted-by":"publisher","first-page":"15584","DOI":"10.1038\/ncomms15584","article-title":"Synergistic\nIL-6 and IL-8 Paracrine Signalling Pathway\nInfers a Strategy to Inhibit Tumour Cell Migration","volume":"8","author":"Jayatilaka","year":"2017","journal-title":"Nat. Commun."},{"issue":"3","key":"2026090910072822400_cit55","doi-asserted-by":"publisher","first-page":"867","DOI":"10.3390\/jcm9030867","article-title":"Evaluation\nof Proinflammatory, Nf-Kappab Dependent Cytokines: Il-1\u03b1, Il-6,\nIl-8, and TNF-\u03b1 in Tissue Specimens and Saliva of Patients with\nOral Squamous Cell Carcinoma and Oral Potentially Malignant Disorders","volume":"9","author":"Babiuch","year":"2020","journal-title":"J. Clin. Med."},{"issue":"4","key":"2026090910072822400_cit56","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s12282-021-01221-4","article-title":"Overexpression of SERPINA3\nPromotes Tumor Invasion and Migration, Epithelial-Mesenchymal-Transition\nin Triple-Negative Breast Cancer Cells","volume":"28","author":"Zhang","year":"2021","journal-title":"Breast\nCancer"},{"issue":"1","key":"2026090910072822400_cit57","doi-asserted-by":"publisher","first-page":"6390","DOI":"10.1080\/21655979.2021.1968777","article-title":"Nucleoporin 160 (NUP160) Inhibition Alleviates Diabetic Nephropathy\nby Activating Autophagy","volume":"12","author":"Xie","year":"2021","journal-title":"Bioengineered"},{"issue":"3","key":"2026090910072822400_cit58","doi-asserted-by":"publisher","first-page":"421","DOI":"10.17219\/acem\/62120","article-title":"IL-6, IL-8\nand TNF-\u03b1 Levels Correlate with Disease Stage in Breast Cancer\nPatients","volume":"26","author":"Ma","year":"2017","journal-title":"Advances in Clinical and Experimental\nMedicine"},{"issue":"July","key":"2026090910072822400_cit59","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.imlet.2020.09.006","article-title":"Regulation of Cellular\nImmunity by Activating Transcription Factor 4","volume":"228","author":"Mukherjee","year":"2020","journal-title":"Immunol. Lett."},{"key":"2026090910072822400_cit60","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting\nthe RAS\/RAF\/MAPK Pathway\nfor Cancer Therapy: From Mechanism to Clinical Studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"8","key":"2026090910072822400_cit61","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1054\/bjoc.2001.2044","article-title":"Cross-Talk between Signalling Pathways\nand the Multidrug\nResistant Protein MDR-1","volume":"85","author":"Ding","year":"2001","journal-title":"Br. J. Cancer"},{"issue":"6","key":"2026090910072822400_cit62","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1158\/1535-7163.MCT-13-0446","article-title":"MAPK Pathway Inhibition Enhances the Efficacy of an\nAnti-Endothelin B Receptor Drug Conjugate by Inducing Target Expression\nin Melanoma","volume":"13","author":"Asundi","year":"2014","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"2026090910072822400_cit63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-024-12005-2","article-title":"EGR1Mediates MDR1 Transcriptional Activity Regulating Gemcitabine\nResistance in Pancreatic Cancer","volume":"24","author":"Yang","year":"2024","journal-title":"BMC Cancer"},{"issue":"59","key":"2026090910072822400_cit64","doi-asserted-by":"publisher","first-page":"99901","DOI":"10.18632\/oncotarget.21914","article-title":"PD-1\/PD-L1 Interaction up-Regulates MDR1\/P-Gp Expression\nin Breast Cancer Cells via PI3K\/AKT and MAPK\/ERK Pathways","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"2026090910072822400_cit65","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1038\/s41467-024-46811-w","article-title":"Combined\nKRAS-MAPK Pathway Inhibitors and HER2-Directed Drug Conjugate Is Efficacious\nin Pancreatic Cancer","volume":"15","author":"Bulle","year":"2024","journal-title":"Nat. Commun."},{"issue":"15","key":"2026090910072822400_cit66","first-page":"5926","article-title":"Ubiquitin\/26S\nProteasome-Mediated Degradation of Topoisomerase I as a Resistance\nMechanism to Camptothecin in Tumor Cells","volume":"61","author":"Desai","year":"2001","journal-title":"Cancer\nRes."}],"container-title":["ACS Nano Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsnanomed.6c00097","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/anmafm\/article-pdf\/1\/8\/2071\/65392737\/acsnanomed.6c00097.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/anmafm\/article-pdf\/1\/8\/2071\/65392737\/acsnanomed.6c00097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:28:06Z","timestamp":1788967686000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/anmafm\/article\/1\/8\/2071\/5177543\/Intracellular-Nanopharmacology-of-Trastuzumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":66,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,7,2]]},"published-print":{"date-parts":[[2026,9,9]]}},"URL":"https:\/\/doi.org\/10.1021\/acsnanomed.6c00097","relation":{},"ISSN":["3067-5928"],"issn-type":[{"value":"3067-5928","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]}}}